Rigel Pharmaceuticals Inc (RIGL)

3.05
0.10 3.39
NASDAQ : Health Care
Prev Close 2.95
Open 2.96
Day Low/High 2.93 / 3.06
52 Wk Low/High 1.88 / 3.68
Volume 719.38K
Avg Volume 1.32M
Exchange NASDAQ
Shares Outstanding 122.29M
Market Cap 350.96M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Immunomedics, Mylan Lead Biotech Movers

Immunomedics, Mylan Lead Biotech Movers

Investors weren't completely distracted by the Affordable Care Act debate.

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 18% Using Options

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 18% Using Options

Investors eyeing a purchase of Rigel Pharmaceuticals Inc stock, but cautious about paying the going market price of $2.79/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2019 put at the $2.50 strike, which has a bid at the time of this writing of 45 cents.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen

Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen

Ironwood Pharmaceuticals, Rigel Pharmaceuticals and FibroGen were among the biotech stock movers in premarket trading on Monday.

Rigel Provides Business Updates And Preliminary Data In IgA Nephropathy

Rigel Provides Business Updates And Preliminary Data In IgA Nephropathy

Announces Presentation at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco

First Week Of RIGL February 2017 Options Trading

First Week Of RIGL February 2017 Options Trading

Investors in Rigel Pharmaceuticals Inc saw new options begin trading this week, for the February 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the RIGL options chain for the new February 2017 contracts and identified the following put contract of particular interest.

First Week of January 2017 Options Trading For Rigel Pharmaceuticals (RIGL)

First Week of January 2017 Options Trading For Rigel Pharmaceuticals (RIGL)

Investors in Rigel Pharmaceuticals Inc saw new options become available this week, for the January 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the RIGL options chain for the new January 2017 contracts and identified the following put contract of particular interest.

Rigel Expands Leadership Team In Research And Business Development

Rigel Expands Leadership Team In Research And Business Development

Reaffirms research focus and IRAK program plans

Short Interest Moves 115.3% Higher For RIGL

Short Interest Moves 115.3% Higher For RIGL

The most recent short interest data has been released for the 09/15/2016 settlement date, which shows a 2,693,273 share increase in total short interest for Rigel Pharmaceuticals Inc , to 5,029,294, an increase of 115.29% since 08/31/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Interesting RIGL Put And Call Options For November 18th

Interesting RIGL Put And Call Options For November 18th

Investors in Rigel Pharmaceuticals Inc saw new options begin trading this week, for the November 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the RIGL options chain for the new November 18th contracts and identified one put and one call contract of particular interest.

Rigel Restructures To Focus On Fostamatinib Commercialization

Rigel Restructures To Focus On Fostamatinib Commercialization

Hires Eldon Mayer as first Chief Commercial Officer, Founder Donald Payan Retires

Rigel Pharma (RIGL) Stock Jumps on Study Results, Piper Jaffray Ups Price Target

Rigel Pharma (RIGL) Stock Jumps on Study Results, Piper Jaffray Ups Price Target

Piper Jaffray increased its price target on Rigel Pharma (RIGL) stock on Tuesday following a late-stage study win for an experimental drug.

Markets Very Sluggish as August Nears an End

Markets Very Sluggish as August Nears an End

Even concerns about a possible Fed rate hike do not appear to be affecting traders.

Rigel Pharma Claims Late-Stage Study Win for Blood Platelet Drug

Rigel Pharma Claims Late-Stage Study Win for Blood Platelet Drug

The 18% response rate for fostamatinib in the Rigel phase III study was on the lower end of investor expectations.

Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP

Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP

Conference call and webcast today at 8:00 AM Eastern Time

Rigel Pharmaceuticals (RIGL) Weak On High Volume Today

Rigel Pharmaceuticals (RIGL) Weak On High Volume Today

Trade-Ideas LLC identified Rigel Pharmaceuticals (RIGL) as a weak on high relative volume candidate